In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
News|Podcasts|April 21, 2026
ACT Brief: Plausible Mechanism Pathway Implementation Steps, Behavioral Science in Trial Design, and Psychedelic Drug Accelerated Review
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we explore practical steps sponsors can take to prepare for the plausible mechanism framework, how behavioral science addresses root causes of recruitment and diversity challenges, and FDA acceleration of psychedelic therapy reviews through executive order.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In the final segment of her video
interview , Mwango Kashoki, MD, MPH, senior vice president and global head of regulatory strategy at Parexel, outlined steps sponsors can take today to avoid delays as plausible mechanism guidance evolves. Early FDA engagement, robust non-clinical programs, adaptive trial designs, and strong confirmatory evidence packages position organizations to navigate the framework effectively as finalization approaches. - In a new
FAQ , behavioral science reveals how recruitment failures and underrepresentation trace to early design decisions rather than late-stage recruitment efforts. Reframing enrollment as a design problem—examining eligibility criteria, visit cadence, site capacity, and geographic access before protocol finalization—prevents costly delays and improves feasibility through observation of real workflows rather than assumptions. - President Trump signed an executive
order directing FDA to accelerate review of psychedelic therapies for mental health conditions, with initial focus on veterans with PTSD and treatment-resistant depression. The action signals potential for compressed regulatory timelines and possible Right to Try pathways, though questions remain about long-term safety data and clinical frameworks for these emerging treatments.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
Trending on Applied Clinical Trials Online
1
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
2
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
3
Beyond the Molecule: Why Radiopharmaceutical Trials Require a New Operating Model
4
Operation TrialBlazer Leveraging New and Anticipated US Policy Changes in Early Development
5